The iconic rise of Viagra has firmly established as a benchmark of pharmaceutical success, but its position within the broader sector now presents questions about long-term returns . Generic versions are undercutting market share, leading to anxieties that investing in companies heavily reliant to Viagra's once-dominant position could be a problema